Abstract
Current antiretroviral regimens are limited by issues of potency, adherence, toxicity, resistance and cost. With these limitations and the realisation that eradication of HIV infection currently is not possible, there is enthusiasm for strategies that allow discontinuation of medications, such as the structured treatment interruption (STI). STI is hypothesised to have benefits in three distinct clinical scenarios: acute treated infection, chronic treated infection with controlled viraemia, and chronic treated infection without controlled viraemia (salvage therapy).
In patients with acute treated HIV infection, STI may preserve or enhance cellular immune responses to allow continued virological suppression in the absence of ongoing treatment. The Berlin patient presented with acute HIV infection prior to seroconversion and received antiretroviral therapy. After two treatment interruptions (for intercurrent infections), he permanently discontinued therapy and remained virologically suppressed for 2 years. Investigators from Massachusetts General Hospital described eight patients with acute or early HIV infection who received treatment and then underwent one or two STI. After the STIs, five of eight patients showed enhanced cellular immune responses and continued with virological suppression off treatment for a median of 2.7 years.
In patients with chronic treated infection with controlled viraemia, STI may enhance immune responses as in the case of acute infection, or may allow decreased drug exposure and toxicity. Investigators from the National Institutes of Health enrolled 18 patients with chronic HIV infection and virological suppression while taking antiretroviral regimens. With a single STI, all patients rebounded, although one (6%) ultimately continued off therapy with virological suppression. The largest study of STI is the Spanish Swiss Intermittent Treatment Trial in which 128 patients with chronic suppressed HIV infection on antiretroviral therapy underwent four cycles of STI. At 52 weeks, 17% had suppressed viral load levels of <5000 copies/ml in the absence of therapy.
In patients with chronic treated infection without controlled viraemia (salvage therapy), STI promotes a shift from resistant to wild-type (i.e. no mutations) virus. In the Hamburg cohort, the shift to wild-type virus was seen in 28 of 45 heavily treatment-experienced patients after an STI. Seventy-two percent of these patients experienced a virological response on a subsequent regimen, although many ultimately experienced virological rebound. In the San Francisco cohort, a shift to wild-type virus was seen in 15 of 17 protease inhibitor-experienced patients and six of these patients achieved virological suppression to <200 copies/ml on a new regimen.
Risks associated with STI include increases in viral load levels with the risk of loss of virological control (i.e. failure to resuppress on therapy), repopulation of viral reservoirs and antiretroviral resistance, and decreases in CD4+ cell counts with the risk of loss or dysregulation of immune function and the occurrence of clinical events. Other risks include acute retroviral syndrome and the recurrence of short-term adverse effects.
Currently, STI cannot be recommended as part of routine clinical care. Prospective studies are needed to assess the risks and benefits of this strategy in all clinical settings.
Similar content being viewed by others
References
Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–60
Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1.EuroSIDA Study Group. Lancet 1998; 352: 1725–30
Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291–5
Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295–300
Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94: 13193–7
Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340: 1683–4
Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407: 523–6
Davey Jr RT, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999; 96: 15109–14
Fagard C, Lebraz M, Gunthard H, et al. SSITT: a prospective trial of strategic treatment interruptions in 128 patients [abstract no.357]. In: Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4–8; Chicago (IL), 1500
Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14: 2857–67
Miller V, Sabin C, Hertogs K, et al. Antiretroviral treatment interruptions in patients with treatment failure: analyses from the Frankfurt HIV Cohort [abstract]. Antiviral Ther 2000; 5: 22
Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344: 472–80
Deeks S, Wrin T, Hoh R, et al. Response to salvage therapy in patients undergoing a structured treatment interruption [abstract no.292]. In: Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4–8; Chicago (IL), 130
Wahren B, Morfeldt-Mansson L, Biberfeld G, et al. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol 1987; 61: 2017–23
Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999; 5: 518–25
Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278: 1447–50
Ortiz GM, Nixon DF, Trkola A, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999; 104: R13–8
Ruiz L, Martinez-Picado J, Romeu J, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000; 14: 397–403
Papasavvas E, Ortiz GM, Gross R, et al. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis 2000; 182: 766–75
Ruiz L, Carcelain G, Martinez-Picado J, et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15: F19–27
Garcia F, Plana M, Ortiz GM, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15: F29–40
Fauci AS. Host factors in the pathogenesis of HIV disease: implications for therapeutic strategies [abstract no.S16]. In: Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4–8; Chicago (IL), 285
Dybul M, Chun TW, Yoder C, et al. Short-cycle intermittent HAART: a pilot study [abstract no.354]. In: Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4–8; Chicago (IL), 149
Neumann AU, Tubiana R, Calvez V, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS 1999; 13: 677–83
Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000; 6: 82–5
Dorman KS, Kaplan AH, Lange K, et al. Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1? J Acquir Immune Defic Syndr 2000; 25: 398–402
Bonhoeffer S, Rembiszewski M, Ortiz GM, et al. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS 2000; 14: 2313–22
Daar ES, Bai J, Hausner MA, et al. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion. Ann Intern Med 1998; 128: 827–9
Colven R, Harrington RD, Spach DH, et al. Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection. Ann Intern Med 2000; 133: 430–4
Kilby JM, Goepfert PA, Miller AP, et al. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: a case report. Ann Intern Med 2000; 133: 435–8
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gulick, R.M. Structured Treatment Interruption in Patients Infected with HIV. Drugs 62, 245–253 (2002). https://doi.org/10.2165/00003495-200262020-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200262020-00001